Did you miss our recent investor webinar this morning? No worries, the recording is now on our website https://bit.ly/3Ticp41 In this session Dr Kilian Kelly and Dr Mathias Kroll Ph.D. M.B.A. (IMD) GAICD provided the latest updates on Cynata's innovative stem cell therapies and progress on key trials, as well as an overview of the partnering strategy. #investors #biotech #stemcells #ICYMI
Cynata Therapeutics
Biotechnology Research
Cremorne, Victoria 3,646 followers
A Next Generation Stem Cell Therapeutics Company
About us
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
- Website
-
http://www.cynata.com
External link for Cynata Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cremorne, Victoria
- Type
- Public Company
- Specialties
- Stem cells, MSCs, and iPSCs
Locations
-
Primary
Get directions
100 Cubitt St
L3
Cremorne, Victoria 3121, AU
Employees at Cynata Therapeutics
-
John (jp) Popolizio (CFCS CIPT CIPP/E FIP CISSP)
Global DPO & CSO as a Service, Global Compliance Smart Tools & Services, Regulatory Representation, Whistleblowing Disclosure & Case Mgt, AI…
-
Peter Webse
Director-Governance Corporate
-
Harsha Gupta
Senior Manager, Manufacturing and Process Development at Cynata Therapeutics
-
Anna Hanks
Senior Clinical Operations Manager at Cynata
Updates
-
📅 Join us for our upcoming investor webinar on Thursday, 5 September at 9:30am. CEO & Managing Director Dr Kilian Kelly will be presenting alongside Chief Business Officer Dr Mathias Kroll. This is your chance to hear the latest updates re clinical trial milestones and partnering strategy, and ask your questions. Register here to reserve your spot: https://bit.ly/3Z941aL #biotech #investor #webinar #ASX
-
-
Cynata Therapeutics reposted this
Our study demonstrating efficacy of Cymerus MSCs in a pulmonary fibrosis model has been published in Biomedicine & Pharmacotherapy - many thanks to Chrishan Samuel and everyone else involved https://lnkd.in/eZ5mQqVM
Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness
sciencedirect.com
-
Dr Kilian Kelly updates Proactive on Cynata following his presentation at the Bioshares Biotech Summit
Cynata Therapeutics Ltd (ASX:CYP) CEO and managing director Dr Kilian Kelly is in the Proactive studio following the 18th annual #BiosharesBiotechSummit in Perth. Cynata is an Australian #StemCell and #RegenerativeMedicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson’s group, which included the first successful isolation of human embryonic stem cells in 1998 and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM’s pioneering iPSC research. Watch at #Proactive #ProactiveInvestors #Biotech #Biopharmaceutcials https://lnkd.in/e3z7hFE8
Cynata Therapeutics talks 18th annual Bioshares Biotech Summit
https://www.youtube.com/
-
Cynata will acquire the groundbreaking wound dressing technology developed by TekCyte Limited. This innovative technology is a key component of our Cymerus™ iPSC-derived MSC topical wound dressing product candidate, CYP-006TK, currently undergoing a Phase 1 clinical trial for diabetic foot ulcers. Read today’s announcement here: https://bit.ly/3IhTz71 #stemcells #innovation #diabetes #woundtreatment # #newsalert
-
-
Have you registered yet? #webinar #ASX #stemcells #biotech
Watch our webinar with Cynata Therapeutics, featuring Managing Director and CEO Dr. Kilian Kelly. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Kilian any questions about CYP that you may have. Key topics: - Cynata's unique proposition compared to other stem cell products on the market - Cynata’s aGVHD trial and the publication in Nature Medicine - Strategy for commercial partnerships Register here: https://hubs.ly/Q02CXfRB0 #asx #shares #stocks
-
-
Register now for an exclusive Sharewise webinar featuring Managing Director and CEO Dr Kilian Kelly. Discover how Cynata’s Cymerus™ stem cell platform is revolutionising regenerative medicine and get the latest updates on our clinical trials. Date: Thursday 27 June Time: 2pm AEST Don't miss this chance to ask Dr Kelly your questions during the live Q&A. Register here: https://bit.ly/3zcAAJO #webinar #stemcelltherapy #biotech #regenerativemedicine #ASX
-
-
Cynata has been featured in Independent Investment Research’s Movers & Shakers report for May. The piece highlights our continued clinical trial advancements and share price growth. Read the full report here: https://bit.ly/4aMcToM #biotech #Cynata #stemcells #innovation
Movers & Shakers - Pharma & Biotech - Independent Investment Research
listcorp.com
-
Cynata's CEO Kilian Kelly will present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar on 13 June 2024 at 2pm AEST. Register here: https://lnkd.in/eYtY2De4
-
-
#ICYMI John Rasko AO discussed the second paper published in Nature Medicine regarding our aGVHD trial. Link to listen below.
Great story on this week’s Australian Broadcasting Corporation (ABC) #healthreport with the illustrious Dr Norman Swan and erudite #tegantaylor discussing the results of our first demonstration of two year safety results in the clinical trial of #reprogrammed human cells sponsored by Cynata Therapeutics https://lnkd.in/gyUns-2y Royal Prince Alfred Hospital NSW Health Sydney Local Health District University of Sydney ISCT, International Society for Cell & Gene Therapy STEMCELL Science News American Society of Gene & Cell Therapy Phacilitate #stemcell #pluripotent
The future of transplant technology - ABC listen
abc.net.au